GPX4 acts as a central inhibitor of ferroptosis in cancer cells, which enhances the cytotoxicity of chemotherapeutic agents in breast cancer as well as the sensitivity to radiotherapy, and thus GPX4 expression level is negatively correlated with the prognosis of breast cancer patients (Song et al., 2021; Ubellacker et al., 2020). This evidence concerns the gene GPX4 and cancer.